Announced
Completed
Financials
Tags
Single Bidder
Reverse Takeover
Private
United States
Merger
pharmaceutical company
Pharmaceuticals
Majority
Acquisition
Domestic
De-SPAC
Friendly
Completed
Synopsis
Coeptis Therapeutics, a pharmaceutical company focused on the development of innovative therapeutics and technologies, went public via a SPAC merger with Bull Horn in a $175m deal. "Today's announcement is a key milestone for Coeptis as it gains access to the capital needed to advance our product portfolio highlighted by CD38-GEAR-NK and CD38-Diagnostic. The combination of CD38-GEAR-NK and CD38-Diagnostic has the potential to provide a more targeted administration of anti-CD38 mAbs in the treatment of cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia," David Mehalick, Coeptis Therapeutics President and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.